-
公开(公告)号:US20230133671A1
公开(公告)日:2023-05-04
申请号:US17904570
申请日:2021-02-19
Applicant: EPIZYME, INC.
Inventor: Maria Alejandra RAIMONDI , Jennifer Anne TOTMAN , Vinny MOTWANI , Katherine Louise COSMOPOULOS , John LAMPE
IPC: A61K31/496 , A61K31/407 , A61K45/06
Abstract: The present disclosure provides SETD2 protein inhibitors, and methods, compositions, and kits for treating diseases, disorders, or conditions in a subject with a SETD2 protein inhibitor and, optionally, a second therapeutic agent, wherein the second therapeutic agent comprises one or more glucocorticoid receptor agonists, one or more immunomodulatory drugs, one or more proteasome inhibitors, one or more Bcl-2 inhibitors, one or more pleiotropic pathway modulators, one or more XPO1 inhibitors, one or more histone deacetylase inhibitors, or one or more EZH2 inhibitors, or a combination thereof.
-
公开(公告)号:US20230049113A1
公开(公告)日:2023-02-16
申请号:US17294959
申请日:2019-11-26
Applicant: EPIZYME, INC.
IPC: A61K31/404 , A61P35/00 , A61K31/4985 , A61K31/496 , A61K31/438 , A61K31/541 , A61K31/4439 , A61K31/437 , A61K31/5377 , A61K31/407 , A61K31/422 , A61K31/519 , A61K31/4709 , A61K31/551 , A61K31/454 , A61K31/55 , A61K31/439 , A61K31/506 , A61K31/4245 , A61K31/433 , A61K31/4725 , A61K31/5386 , A61K31/427 , A61K31/415 , A61K31/4995 , A61K31/4196 , A61K31/4155 , A61K31/517 , A61K31/4178 , A61K31/537 , A61K31/499
Abstract: The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancers that overexpress the histone methyltransferase WHSC1, e.g., t(4; 14) multiple myeloma, by administering to a subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.
-
公开(公告)号:US20210002645A1
公开(公告)日:2021-01-07
申请号:US16639424
申请日:2018-08-14
Applicant: EPIZYME, INC.
Inventor: Alexandra Rose Grassian , Michael THOMENIUS , Jennifer Anne TOTMAN
IPC: C12N15/113 , C07K16/40 , C12N9/22 , C12N15/11 , A61K38/46 , A61K31/7088 , A61K31/7076 , A61K39/395
Abstract: The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancer, i.e., pancreatic cancer or esophageal cancer, by administering to a human subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.
-
-